This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitoussi, F.
Right arrow Articles by Bingen, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitoussi, F.
Right arrow Articles by Bingen, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2372-2375, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Killing Activities of Trovafloxacin Alone and in Combination with beta -Lactam Agents, Rifampin, or Vancomycin against Streptococcus pneumoniae Isolates with Various Susceptibilities to Extended-Spectrum Cephalosporins at Concentrations Clinically Achievable in Cerebrospinal Fluid

Frederic Fitoussi,1 Catherine Doit,1 Pierre Geslin,2 and Edouard Bingen1,*

Service de Microbiologie, Hôpital Robert Debré, 75019 Paris,1 and Centre National de Référence des Pneumocoques, Centre Hospitalier de Créteil, 94010 Créteil,2 France

Received 8 March 1999/Returned for modification 7 June 1999/Accepted 2 August 1999

The killing activities of trovafloxacin alone and in combination with beta -lactam agents (extended-spectrum cephalosporins, meropenem), rifampin, or vancomycin were evaluated against 20 genotypically characterized Streptococcus pneumoniae isolates for which amoxicillin MICs were >= 4 µg/ml (cefotaxime MICs, >= 4 µg/ml for six strains) at concentrations clinically achievable in cerebrospinal fluid. At 6 h the mean killing activity of trovafloxacin alone (range, 2.6 to 2.9 log10 CFU/ml) did not vary significantly according to the susceptibility of the strains to beta -lactam agents. The activities of trovafloxacin or vancomycin added to the beta -lactam agents and the combination trovafloxacin-vancomycin were additive or indifferent. Against the ceftriaxone-resistant isolates, the killing activity of the combination of a beta -lactam agent and trovafloxacin did not differ significantly from that of a beta -lactam agent and vancomycin.

* Corresponding author. Mailing address: Service de Microbiologie, Hôpital R. Debré, 48 Bd. Sérurier, 75019 Paris, France. Phone: 33 (1) 40 03 23 40. Fax: 33 (1) 40 03 24 50. E-mail: edouard.bingen{at}rdb.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2372-2375, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Henderson-Begg, S. K., Livermore, D. M., Hall, L. M. C. (2006). Effect of subinhibitory concentrations of antibiotics on mutation frequency in Streptococcus pneumoniae. J Antimicrob Chemother 57: 849-854 [Abstract] [Full Text]  
  • Desbiolles, N., Piroth, L., Lequeu, C., Neuwirth, C., Portier, H., Chavanet, P. (2001). Fractional Maximal Effect Method for In Vitro Synergy between Amoxicillin and Ceftriaxone and between Vancomycin and Ceftriaxone against Enterococcus faecalis and Penicillin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3328-3333 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»